Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer

Hidetoshi Eguchi, Hiroaki Nagano, Masahiro Tanemura, Yutaka Takeda, Shigeru Marubashi, Shogo Kobayashi, Koichi Kawamoto, Hiroshi Wada, Naoki Hama, Hirofumi Akita, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background/Aims: In order to improve the poor prognosis of pancreatic cancer, a combination therapy consisting of preoperative chemoradiotherapy, surgery and postoperative chemotherapy may be an ideal strategy; nevertheless, the influence of preoperative therapy to postoperative therapy is not investigated. Methodology: Thirty patients with resectable pancreatic ductal adenocarcinoma were enrolled. A 40Gy of radiation (2Gy/day x 20 fractions/4 weeks) was administered together with intravenous infusion of gemcitabine (800mg/m2, days 1, 8 and 15) before surgery. Surgery was performed 3-7 weeks after the final fraction of radiation, and postoperative chemotherapy consisting of 1000mg/m2 gemcitabine (days 1, 8 and 15 every 4 weeks for 6 cycles) was started within 8 weeks after surgery. Results: All 30 patients successfully completed preoperative therapy. Re-staging after such therapy showed radiologically unresectable disease in 4 patients and 1 patient rejected surgery. Among the 25 patients who underwent laparotomy, 21 underwent curative resection. After curative resection, 4 were inadequate in performance status, thus postoperative therapy could not be started. Ten patients completed postoperative adjuvant therapy. Conclusions: The combination therapy for resectable pancreatic cancer seems a feasible and effective approach, though preoperative therapy may reduce the feasibility of postoperative therapy.

Original languageEnglish
Pages (from-to)904-911
Number of pages8
Issue number124
Publication statusPublished - Jun 2013

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer'. Together they form a unique fingerprint.

Cite this